End of federal support means big COVID-19 costs for insurers

Health insurance companies are urging regulators to establish price ceilings for COVID-19 vaccines and therapeutics, cautioning that costs will skyrocket without them. 

Once the federal supply of coronavirus vaccines and treatments runs out, health insurers, employers and pharmacy benefit managers must strike deals with pharmaceutical companies on the prices for the Moderna, Pfizer-BioNTech, Johnson & Johnson and Novavax vaccines and…